Taphalgin Completes Another Successful Phase III Clinical Study for Postoperative Pain

01.04.2023

In our continuous endeavor to improve pain management solutions, we are elated to share the triumphant conclusion of Phase III clinical study for Taphalgin. This trial, centered on pain syndromes in the early postoperative period, utilized a dosage of 4mg administered thrice daily. We're now a step closer to making Taphalgin accessible to patients in need worldwide.

Taphalgin Completes Another Successful Phase III Clinical Study for Postoperative Pain

About

Recent news

Taphalgin Completes Another Successful Phase III Clinical Study for Postoperative Pain

Phase III Study Validates Taphalgin‘s Efficacy for Cancer Pain Management

Сontacts

©2016-2023 PVP LABS PTE. LTD